Guanidine and 2-aminoimidazoline aromatic derivatives as α2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants

Journal of Medicinal Chemistry

Volumn 51, Issue 11, 2008, Pages 3304-3312

  Rodriguez, Fernando ^a   Rozas, Isabel ^a   Ortega, Jorge E ^b,c   Erdozain, Amaia M ^b,c   Meana, J Javier ^b,c   Callado, Luis F ^b,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 IMIDAZOLIDINYLIMINO) 3,4 DIMETHYLBENZENE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 AMINOIMIDAZOLINE DERIVATIVE; 2,6 BIS(2 IMIDAZOLIDINYLIMINO) 9,10 DIHYDROANTHRACENE; 2,6 DIGUANIDINO 9,10 DIHYDROANTHRACENE; 4,4' BIS(2 IMIDAZOLIDINYLIMINO) 1,2 DIPHENYLETHANE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BRIMONIDINE; CLONIDINE; GUANIDINE DERIVATIVE; IDAZOXAN; IMIDAZOLIDIN 2 YLIDENE (5,6,7,8 TETRAHYDRONAPHTHALEN 2 YL)AMINE; MIANSERIN; MIRTAZAPINE; N (5,6,7,8 TETRAHYDRONAPHTHALEN 2 YL)GUANIDINE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; DEPRESSION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOOD-BRAIN BARRIER; BRAIN; GUANIDINES; HUMANS; IMIDAZOLES; IMIDAZOLINES; MALE; MICRODIALYSIS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES;

EID: 44949091369     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800026x     Document Type: Article

References (42)

1. http://www.who.int/mental_health/management/depression/definition/en/.
2. Elhwuegi, A. S. Central monoamines and their role in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 435-451.
3. (a) Callado, L. F.; Meana, J. J.; Grijalba, B.; Pazos, A.; Sastre, M.; García-Sevilla, J. A. Selective increase of alpha2a-adrenoceptor agonist binding sites in brains of depressed suicide victims. J. Neurochem. 1998, 70, 1114-1123.
4. (b) Gonzalez-Maeso, J.; Rodriguez-Puertas, R.; Meana, J. J.; Garcia-Sevilla, J. A.; Guimon, J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha2A-adrenoceptors. Mol. Psychiatry 2002, 7, 755-767.
5. Mateo, Y.; Fernandez-Pastor, B.; Meana, J. J. Acute and chronic effects of desipramine and clorgyline on alpha2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br. J. Pharmacol. 2001, 133, 1362-1370.
6. Fernandez-Pastor, B.; Meana, J. J. In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha2-adrenoceptors. Eur. J. Pharmacol. 2002, 442, 225-229.
7. Devoto, P.; Flore, G.; Pani, L.; Gessa, G. L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol. Psychiatry 2001, 6, 657-664.
8. Mateo, Y.; Pineda, J.; Meana, J. J. Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem. 1998, 71, 790-798.
9. Leonard, B. E. Neuropharmacology of antidepressants that modify central noradrenergic and serotonergic function: a short review. Hum. Psychopharmacol. Clin. 1999, 14, 75-81.
10. Rodriguez, F.; Rozas, I.; Ortega, J. E.; Meana, J. J.; Callado, L. F. Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists, 1: Towards new antidepressants with heteroatomic linkers. J. Med. Chem. 2007, 50, 4516-4527.
11. 2- Imidazoline binding site affinity of a structurally different type of ligands. Bioorg. Med. Chem. 2002, 10, 1525-1533.
12. 3H]RX-821002 binding to membranes and tissue sections. Eur. J. Pharmacol. 1996, 310, 83-93.
13. Fitzgerald, P. B.; Oxley, T. J.; Laird, A. R.; Kulkarni, J.; Egan, G. F.; Daskalakis, Z. J. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Res. 2006, 148, 33-45.
14. Dardonville, C.; Goya, P.; Rozas, I.; Alsasua, A.; Martin, I.; Borrego, M. J. New aromatic iminoimidazolidine derivatives as alpha1-adrenoceptor antagonists: a novel synthetic approach and pharmacological activity. Bioorg. Med. Chem. 2000, 8, 1567-1577.
15. Kim, K. S.; Qian, L. Improve methods for the preparation of guanidines. Tetrahedron Lett. 1993, 48, 7677-7680.
16. (a) Takimiya, K.; Yanagimoto, T.; Yamashiro, T.; Ogura, F.; Otsubo, T. Syntheses and properties of 11,11,12,12-tetracyano-2,6-anthraquin-odimethane (TANT) and its 9,10-dichloro derivative as novel extensive electron acceptors. Bull. Chem. Soc. Jpn. 1998, 71, 1431-1435.
17. (b) Yanagimoto, T.; Takimiya, K.; Otsubo, T.; Ogura, F. 11,11,12,12-Tetracyano-2,6-anthraquinodimethane (TANT) as a novel extensive electron acceptor. J. Chem. Soc., Chem. Commun. 1993, 6, 519-520.
18. Between others: (a) Berlinck, R. G. S.; Kossuga, M. H.; Nascimento, A. M. Guanidine derivatives. Sci. Synth. 2005, 18, 1077-1116.
19. (b) Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. Urethane protected derivatives of 1 -guanylpyrazole for the mild and efficient preparation of guanidines. Tetrahedron Lett. 1993, 34, 3389-3392.
20. (a) Arafa, R. K.; Bran, R.; Wenzler, T.; Tanious, F. A.; Wilson, W. D.; Stephens, C. E.; Boykin, D. W. Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J. Med. Chem. 2005, 48, 5480-5488.
21. (b) Boykin, D. W.; Tidwell, R. R.; Wilson, D. W.; Brun, R.; Arafa, R. K.; Stephens, C. E. Preparation of Fused Ring Dicationic Antiprotozoals and Prodrugs Thereof. Patent WO 2005051296 A2 20050609, CAN 143:43696, AN 2005:493466, 2005.
22. Balko, T. W. 2-(Substitutedamino)-N-(3-substitutedphenyl)-2- imidazoline-1-carbothioamides. Patent US 4195092 19800325, CAN 93: 71781, AN 1980:471781, 1980.
23. Between others: (a) Katritzky, A. R.; Khashab, N. M.; Bobrov, S. The preparation of 1,2,3-trisubstituted guanidines. Helv. Chim. Acta 2005, 88, 1664-1675.
24. (b) Trani, A.; Bellasio, E. Synthesis of 2-chloro-2-imidazoline and its reactivity with aromatic amines, phenols, and thiophenols. J. Heterocycl. Chem. 1974, 11, 257-262.
25. (a) Between others: Hirashima, A.; Pan, C.; Shinkai, K.; Tomita, J.; Kuwano, E.; Taniguchi, E.; Eto, M. Quantitative structure-activity studies of octopaminergic agonists and antagonists against nervous system of Locusta migratotia. Bioorg. Med. Chem. 1998, 6, 903-910.
26. Glennon, R. A.; Daoud, M. K.; Dukat, M.; Teitler, M.; Herrick-Davis, K.; Purohit, A.; Syed, H. Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: a QSAR study. Bioorg. Med. Chem. 2003, 11, 4449-4454.
27. Between others: Paul, R.; Hallett, W. A.; Hanifin, J. W.; Reich, M. F.; Johnson, B. D.; Lenhard, R. H.; Dusza, J. P.; Kerwar, S. S.; Lin, Y. I.; Pickett, W. C.; Seifert, C. M.; Torley, L. W.; Tarrant, M. E.; Wrenn, S. Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors. J. Med. Chem. 1993, 36, 2716-2725.
28. Between others: (a) Lefevre-Groboillot, D.; Boucher, J.-L.; Stuehr, D. J.; Mansuy, D. Relationship between the structure of guanidines and N-hydroxyguanidines, their binding to inducible nitric oxide synthase (iNOS) and their iNOS-catalysed oxidation to NO. FEBS J. 2005, 272, 3172-3183.
29. (b) Srivastava, P. K.; Sharma, R. D.; Saleem, M. A convenient method for the preparation of monosubstituted guanidines. Curr. Sci. 1976, 45, 764-765.
30. Between others: (a) Vale-Silva, L. A.; Buchta, V.; Valentova, E. Effect of subinhibitory concentration of some established and experimental antifungal compounds on the germ tube formation in Candida albicans. Folia Microbiol. 2007, 52, 39-43.
31. (b) Min, K.-L.; Steghens, J.-P.; Henry, R.; Doutheau, A.; Collombel, C. Synthesis and differential properties of creatine analogs as inhibitors for human creatine kinase isoenzymes. Eur. J. Biochem. 1996, 238, 446-452.
32. Between others: Clark, R. J.; Isaacs, A.; Walker, J. Derivatives of 3,4-xylidine and related compounds as inhibitors of influenza virus: relationships between chemical structure and biological activity. Br. J. Pharmacol. Chemother. 1958, 13, 424-435.
33. Rose, Y.; Ciblat, S.; Reddy, R.; Belley, A. C.; Dietrich, E.; Lehoux, D.; McKay, G. A.; Poirier, H.; Far, A. R.; Delorme, D. Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC Bioorg. Med. Chem. Lett. 2006, 16, 891-896.
34. (a) Jerushalmy, Z.; Skoza, L.; Zucker, M. B.; Grant, R. Inhibition by guanidino compounds of platelet aggregation induced by adenosine diphosphate. Biochem. Pharmacol. 1966, 15, 1791-1803.
35. (b) Ewins, A. J.; Barber, H. J.; Self, A. D. H. Diguanidine Compounds. Patent GB 516289 19391229, CAN 35:37743, AN 1941:37743, 1939.
36. Wong, W. C.; Jeon, Y. T.; Dhar, T. G. M.; Gluchowski, C. Imidazole and Imidazoline Derivatives as Alpha2-Adrenergic Agonists. Patent WO 9846572 A1 19981022, CAN 129:316226, AN 1998:706207, 1998.
37. Dardonville, C.; Rozas, I.; Alkorta, I. Similarity studies on guanidinium, imidazolinium, and imidazolium cations: toward new Bradykinin antagonists. J. Mol. Graphics Modell. 1998, 16, 150-156.
38. 35S]GTPγS binding to cortical membranes from postmortem human brain. Eur. J. Pharmacol. 2000, 390, 25-36.
39. Fillenz, M. In vivo neurochemical monitoring and the study of behaviour. Neurosci. Biobehav. Rev. 2005, 29, 949-962.
40. It has been reported in the literature that systemic administration of idazoxan (20 mg/kg ip) increased cortical NA release in rats to a maximun of 230% (Dennis et al. J. Pharmacol. Exp. Ther. 1987, 241, 642-649)
41. and systemic administration of RX821002 (3 mg/kg ip) induced a 2-fold increase in dialysate NA concentration from the rat frontal cortex (Wortley et al. Br. J. Pharmacol. 1999, 128, 659-666).
42. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 2nd ed.; Academic Press: Orlando, FL, 1986.